New Drug Decreases Progression of Knee Osteoarthritis

by Ramya Rachamanti on  January 2, 2020 at 9:44 PM Drug News
RSS Email Print This Page Comment bookmark
Font : A-A+

New drug can significantly reduce bone and cartilage progression in knee osteoarthritis. But, it was not very effective in decreasing pain compared to a placebo.
New Drug Decreases Progression of Knee Osteoarthritis
New Drug Decreases Progression of Knee Osteoarthritis

Osteoarthritis of the knee is a painful, disabling condition affecting more than 14 million people in the US and hundreds of millions worldwide.

Show Full Article


The pain of knee osteoarthritis arises from a series of pathologic processes involving articular cartilage, subchondral bone, synovium, meniscus, and other joint structures, ultimately leading to joint failure and pain-related functional limitations.

A team of researchers led by the University of Leeds in UK, sought to test the hypothesis that cathepsin K inhibitor could alleviate osteoarthritis symptoms by reducing degeneration of bone and cartilage.

In a multi-centre study, 244 patients with primary knee osteoarthritis were randomly assigned to receive either 100 or 200 mg daily of MIV-711 or matched placebo for 26 weeks to evaluate the efficacy, safety, and tolerability of MIV-711.

The primary endpoint of the study was change in pain score, but changes in disease progression were also assessed using quantitative MRI outcomes.

The researchers found that compared with placebo, MIV-711 was associated with less bone remodelling, less cartilage volume loss, and lower levels of bone resorption and collagen loss.

However, it showed no beneficial effects on osteoarthritic knee pain.

According to the researchers, further evaluation is needed to confirm the structural benefits of MIV-711 and to determine whether these translate to more tangible benefits on disease symptoms.

The researchers said that while the work is promising, they agree that more research is needed to determine the longer term benefits of MIV-711.

Source: IANS

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions
Diabetes Premium Membership Benefits

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Stay Connected

  • Available on the Android Market
  • Available on the App Store

News Category

News Archive